HALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming GrowthInvestors Business Daily • 11/15/22
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/08/22
Halozyme Therapeutics (HALO) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/25/22
Halozyme Therapeutics (HALO) Down 10.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/08/22
Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028PRNewsWire • 08/16/22
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028PRNewsWire • 08/15/22
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung CancerPRNewsWire • 08/02/22
Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?Zacks Investment Research • 07/08/22
Halozyme Therapeutics (HALO) Up 19.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/09/22